Calithera Biosciences Inc. [NASDAQ: CALA] price plunged by -7.62 percent to reach at -$0.02. The company report on May 3, 2022 that Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022.
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company’s first quarter 2022 financial results will be released on Tuesday, May 10, 2022. Company management will host a conference call on Tuesday, May 10, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com. The call may be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and referring to conference ID 4979639. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on Calithera’s website for 30 days.
A sum of 3224447 shares traded at recent session while its average daily volume was at 2.28M shares. Calithera Biosciences Inc. shares reached a high of $0.2643 and dropped to a low of $0.2336 until finishing in the latest session at $0.24.
The one-year CALA stock forecast points to a potential upside of 89.92. The average equity rating for CALA stock is currently 2.50, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Calithera Biosciences Inc. [CALA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CALA shares is $2.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CALA stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
SVB Leerink have made an estimate for Calithera Biosciences Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on January 05, 2021. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on March 27, 2020, representing the official price target for Calithera Biosciences Inc. stock. Previously, the target price had yet another raise to $7, while H.C. Wainwright analysts kept a Buy rating on CALA stock.
The Average True Range (ATR) for Calithera Biosciences Inc. is set at 0.04, with the Price to Sales ratio for CALA stock in the period of the last 12 months amounting to 2.58. The Price to Book ratio for the last quarter was 2.18, with the Price to Cash per share for the same quarter was set at 0.57.
CALA Stock Performance Analysis:
Calithera Biosciences Inc. [CALA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.78. With this latest performance, CALA shares dropped by -30.08% in over the last four-week period, additionally sinking by -87.51% over the last 6 months – not to mention a drop of -88.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CALA stock in for the last two-week period is set at 34.26, with the RSI for the last a single of trading hit 32.30, and the three-weeks RSI is set at 35.99 for Calithera Biosciences Inc. [CALA]. The present Moving Average for the last 50 days of trading for this stock 0.4029, while it was recorded at 0.2494 for the last single week of trading, and 1.1484 for the last 200 days.
Insight into Calithera Biosciences Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Calithera Biosciences Inc. [CALA] shares currently have an operating margin of -1172.07 and a Gross Margin at +85.29. Calithera Biosciences Inc.’s Net Margin is presently recorded at -1180.39.
Return on Equity for this stock declined to -207.83, with Return on Assets sitting at -120.93.
Calithera Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.40 and a Current Ratio set at 4.40.
Calithera Biosciences Inc. [CALA] Insider Position Details
There are presently around $11 million, or 44.50% of CALA stock, in the hands of institutional investors. The top three institutional holders of CALA stocks are: PRIMECAP MANAGEMENT CO/CA/ with ownership of 10,733,000, which is approximately 1.172% of the company’s market cap and around 1.10% of the total institutional ownership; BVF INC/IL, holding 7,452,331 shares of the stock with an approximate value of $1.94 million in CALA stocks shares; and CITADEL ADVISORS LLC, currently with $0.92 million in CALA stock with ownership of nearly 233.884% of the company’s market capitalization.
Positions in Calithera Biosciences Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 36 institutional holders increased their position in Calithera Biosciences Inc. [NASDAQ:CALA] by around 11,271,367 shares. Additionally, 29 investors decreased positions by around 12,659,785 shares, while 13 investors held positions by with 19,615,304 shares. The mentioned changes placed institutional holdings at 43,546,456 shares, according to the latest SEC report filing. CALA stock had 18 new institutional investments in for a total of 1,782,653 shares, while 14 institutional investors sold positions of 3,402,448 shares during the same period.